"Janus Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit JANUS KINASES.
| Descriptor ID |
D000075242
|
| MeSH Number(s) |
D27.505.519.389.755.500
|
| Concept/Terms |
Janus Kinase Inhibitors- Janus Kinase Inhibitors
- Inhibitors, Janus Kinase
- Kinase Inhibitors, Janus
- JAK Inhibitors
- Inhibitors, JAK
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase Inhibitors".
This graph shows the total number of publications written about "Janus Kinase Inhibitors" by people in this website by year, and whether "Janus Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 2 | 0 | 2 |
| 2023 | 6 | 0 | 6 |
| 2024 | 0 | 4 | 4 |
| 2025 | 4 | 1 | 5 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase Inhibitors" by people in Profiles.
-
Beyond the bowel: three rare complications of upadacitinib therapy in inflammatory bowel disease. J Crohns Colitis. 2026 May 08; 20(5).
-
Safety and Efficacy of Upadacitinib in Patients with Inflammatory Bowel Disease After Liver Transplantation: A Case Series. Dig Dis Sci. 2026 May; 71(5):1711-1715.
-
New Eczematous Eruption in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors. Am J Gastroenterol. 2026 01 01; 121(1):268-273.
-
Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2026 Mar; 24(3):784-793.
-
Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2025 06 01; 64(6):3434-3443.
-
Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: A Multicenter Study. Clin Gastroenterol Hepatol. 2025 Nov; 23(12):2281-2291.e4.
-
Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 11 04; 30(11):2057-2063.
-
Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk. JAMA Netw Open. 2024 11 04; 7(11):e2446336.
-
Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024 May; 11(5):e383-e389.
-
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure. Clin Gastroenterol Hepatol. 2024 10; 22(10):2096-2106.